Ataluren

BNF:: Not listed
Status:: Red
Decision Date:: August 2016

Comments

RED:

NICE HST3: for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. (Decision date - August 2016).
HST22 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. (Decision date - March 2023)

NHS England drug - to be used in line with NHSE commissioning intentions.

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)